Vincerx Pharma Inc :
* VINCERX REPORTS POSITIVE INITIAL CLINICAL DATA FROM ONGOING VIP943 PHASE 1 DOSE-ESCALATION STUDY AND PROVIDES PIPELINE AND CORPORATE UPDATES
* VINCERX PHARMA INC - EXPECTED CASH RUNWAY INTO EARLY 2025
* VINCERX PHARMA INC - VINCERX FOCUSING RESOURCES ON CONTINUED DEVELOPMENT OF VIP943
* VINCERX PHARMA INC - VIP943 DEMONSTRATES PROMISING SAFETY AND TOLERABILITY AND ACHIEVES TWO COMPLETE RESPONSES TO DATE IN PHASE 1 DOSE-ESCALATION STUDY
* VINCERX PHARMA INC - ANTICIPATES PROVIDING ANOTHER DATA UPDATE ON ONGOING PHASE 1 VIP943 STUDY BY END OF YEAR.
Source text for Eikon: Further company coverage:
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。